Equifax Inc.
EFX - NYSE - $175.83 ▲ +%0.12
-
Earnings Tue 21 Jul

Equifax opens the
books on Tuesday evening.

2 analysts' median target is $222[FMP target], stock is $176, +26.3% upside potential. After Q1 +10.1% EPS beat[FMP earnings], the stock moved -7.2%.

summary below
Quick Take - in 40 seconds
B
BUY Council 4/6 - Moonshot 47

B = MoonshotScore 47[9-pillar formula] + Council 4/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $1.7B[FMP est], EPS $2.25[FMP est]. 5 consecutive quarters of beat[FMP earnings].

$2.25 EPS Estimate Last year $2.09 - +13% YoY YoY
5 Beat Streak Expectations beaten consecutively for the last 5 quarters

Q1 EPS +10.1% beat[FMP] but the stock -7.2% D+1[FMP D+1]. John Gamble promised $120.4M CapEx + a sequential decline in Q4 during the Q1 earnings call[John Gamble capex transcript].

Watchlist

5 metrics stand out this quarter.

20% Investor Focus

Mortgage Revenue Growth

mortgage_revenue_growth

Despite a strong Q1, Equifax is maintaining its 2026 mortgage revenue growth guidance of over 20% due to uncertainty related to the Iran conflict.

"We are maintaining our 2026 guidance for mortgage revenue growth of over 20%, consistent with the framework we provided in February, as a stronger-than-expected first quarter mortgage revenue growth is offset by our expectation of current trends of slightly slower growth over the remainder of the year versus our February guide."

- Mark Begor, Chief Executive Officer - Q1 FY26 Earnings Call - April 21, 2026
75 Risk Indicator

Margin Expansion

margin_expansion

Equifax expects to deliver strong full-year margin expansion, excluding FICO, of 75 basis points from operating leverage of strong top-line growth, higher margin new products, and AI-driven productivity.

"We also expect to deliver strong full year margin expansion, excluding FICO of 75 basis points from operating leverage of strong top line growth, higher margin new products and AI-driven productivity."

- Mark Begor, Chief Executive Officer - Q1 FY26 Earnings Call - April 21, 2026
- Investor Focus

Government Revenue Growth

government_revenue_growth

Equifax remains energized about the mid- and long-term growth opportunities for EWS government at both the federal and the state level in meeting new federal requirements regarding accuracy of income validation in Medicaid and SNAP.

"We remain energized about the mid- and long-term growth opportunities for EWS government at both the federal and the state level in meeting new federal requirements regarding accuracy of income validation in Medicaid and SNAP as well as work, education and community engagement requirements and Medicaid benefits."

- Mark Begor, Chief Executive Officer - Q1 FY26 Earnings Call - April 21, 2026
- Investor Focus

TWN Indicator Growth

TWN_indicator_growth

Equifax is delivering TWN income and employment attributes at no cost to its customers to drive credit file share gains and future TWN VOI and VOE growth.

"And as a reminder, Equifax is delivering TWN income and employment attributes at no cost to our customers to drive credit file share gains in TWN VOI and VOE growth in the future."

- Mark Begor, Chief Executive Officer - Q1 FY26 Earnings Call - April 21, 2026
$327 Investor Focus

Capital Allocation

capital_allocation

Equifax has $1.5 billion of capital available in 2026 to invest in both bolt-on M&A and return of cash to shareholders, and returned $327 million to shareholders in Q1.

"In the first quarter, we returned $327 million to shareholders."

- Mark Begor, Chief Executive Officer - Q1 FY26 Earnings Call - April 21, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

Council Score 4 / 6 Bullish

6 investor frameworks. 4 bullish (Ray Dalio, Klarman, Buffett, Munger), 1 bearish (Ken Griffin), 1 neutral (Jim Simons).

How is it calculated? ->
Ray Dalio macro - target upside +26.3%
Ken Griffin flow - 50d MA below
Jim Simons quant - RSI 46
Klarman value - target upside +26.3%
Buffett quality - ROE score 4/5
Munger valuation - target upside +26.3%
Munger's Mindset character & balance sheet lens
Undervalued

Quality business, discounted price.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyStrong
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
45.8 RSI 45.8 balanced, 50d below
MACD
-4.50 price below 50d - resistance dominant
50d MA
$184 stock 4.5% below - short-term resistance
200d MA
$215 stock 18.1% below - long-term pressure
Volume (10d)
-18% decrease - low participation
Resistance
$222
Analyst median target - upgrade trigger if broken
Current
$176
Pre-earnings position
Support
$182
Invalidation - close below this is a technical breakdown
Pattern
Range
$182-$222 band - earnings breakout/breakdown trigger

Past Performance

Equifax's last 8 quarters: 5 consecutive beats.

BEAT
Q2 FY25
$2.00 vs $1.93 est - +3.1%
BEAT
Q3 FY25
$2.04 vs $1.94 est - +0.3%
BEAT
Q4 FY25
$2.09 vs $2.06 est - +5.5%
BEAT
Q1 FY26
$1.86 vs $1.69 est - -7.2%

Q1 (April 21, 2026): EPS $1.86 vs $1.69 est[FMP], +10.1% beat. D+1 movement: -7.2%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $2.18 (no guidance)

Q1: EPS $1.86 vs $1.69 beat[FMP], stock -7.2% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q1 earnings call.

CapEx shock

Q1 CapEx $120.4M[FMP cashflow]. Q1 op margin 17.4%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $2.25 + CapEx discipline
Threshold: EPS > $2.25[FMP est].
Target: Break above median target $222[FMP target]; high target $265[FMP] upper bound.
Scenario B - In-Line
EPS approx $2.25 + CapEx < $120.4M
Threshold: EPS approx $2.25[FMP est], Q4 CapEx < $120.4M[FMP].
Target: Consolidation in the band between current $176[FMP] and median $222[FMP].
Scenario C - Miss
EPS < $2.18 or CapEx >= $120.4M
Threshold: EPS < $2.18[FMP estx0.97].
Target: Current $176 below SMA200 $215[FMP], if rejection continues, $182[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 2 analysts say?

Wall Street Consensus
$222
12-month median target price (+26.3% upside potential)
17
BUY
7
HOLD
0
SELL
Risk Management
$182
Invalidation level - critical support threshold
$184 - 50-day MA (below, -4.5%)
$215 - 200-day MA (below, -18.1%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - EFX Q4 FY26
B

You read it in 5 minutes. When the numbers come out on Tuesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Tuesday evening. The framework is ready on this page: Q4 EPS threshold $2.25[FMP], CapEx threshold "below $120.4M"[John Gamble]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jul 21, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
Jul 22, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Sep 4, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Oct 21, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the EFX earnings preview cover?

This EFX (EFX) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in EFX earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.